SIREN : 438136244
CDC CROISSANCE is a French company founded 24 years ago, specialized in the sector Gestion de fonds. Based in PARIS (75007), this company of category GE shows in 2024 a revenue of 15.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-25
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15 033 190 € | 14 271 287 € | 13 213 221 € | 14 196 351 € | 11 223 749 € | 9 755 093 € | 5 720 848 € | 4 671 151 € |
| Net income | 2 740 012 € | 3 990 503 € | 3 386 796 € | 4 549 731 € | 2 266 879 € | 840 003 € | 1 023 219 € | 946 139 € |
| EBITDA | 3 620 988 € | 5 516 679 € | 4 694 799 € | 6 337 569 € | 3 220 917 € | 954 383 € | 1 633 718 € | 1 336 555 € |
| Net margin | 18.2% | 28.0% | 25.6% | 32.0% | 20.2% | 8.6% | 17.9% | 20.3% |
In 2024, CDC CROISSANCE achieves revenue of 15.0 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +15.7%. Vs 2023: +5%. After deducting consumption (0 €), gross margin stands at 15.0 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 3.6 M€, representing 24.1% of revenue. Warning negative scissor effect: despite revenue change (+5%), EBITDA varies by -34%, reducing margin by 14.6 pts. This reflects costs rising faster than revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 2.7 M€, i.e. 18.2% of revenue. This profit can be retained or distributed to shareholders.
15 033 190 €
15 033 190 €
3 620 988 €
3 718 875 €
2 740 012 €
24.1%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 74%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 17.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.0%
74.372%
17.667%
0.0
47.4%
In 2024, the debt ratio of CDC CROISSANCE (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of CDC CROISSANCE (74.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of CDC CROISSANCE (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 374.47. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.9x. Danger: operating income does not cover interest charges, unsustainable situation.
374.466
0.905
In 2024, the liquidity ratio of CDC CROISSANCE (374.47) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of CDC CROISSANCE (0.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 26 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 125 days. Excellent situation: suppliers finance 99 days of the operating cycle (retail model). WCR is negative (-7 days): operations structurally generate cash. Over 2016-2024, WCR increased by +53%, requiring additional financing.
-301 115 €
26 j
125 j
0 j
-7 j
Based on 62 transactions of similar company sales
in 2024,
the value of CDC CROISSANCE is estimated at
14 109 595 €
(range 4 561 988€ - 31 401 257€).
With an EBITDA of 3 620 988€, the sector multiple of 4.8x is applied.
The price/revenue ratio is 0.30x
(conservative valuation).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 62 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare CDC CROISSANCE with other companies in the same sector:
The revenue of CDC CROISSANCE in 2024 is 15.0 M€.
Yes, CDC CROISSANCE generated a net profit of 2.7 M€ in 2024.
The headquarters of CDC CROISSANCE is located in PARIS (75007), in the department Paris.
The tax return of CDC CROISSANCE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
CDC CROISSANCE operates in the sector Gestion de fonds (NAF code 66.30Z). See the 'Sector positioning' section above to compare the company with its competitors.